Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
Courtney D DiNardo,Divij Verma,Natalia Baran,Tushar D Bhagat,Anna Skwarska,Alessia Lodi,Kapil Saxena,Tianyu Cai,Xiaoping Su,Veronica A Guerra,Gowri Poigaialwar,Vinitha M Kuruvilla,Sergej Konoplev,Shanisha Gordon-Mitchell,Kith Pradhan,Srinivas Aluri,G Lavender Hackman,Sovira Chaudhry,Meghan Collins,Shannon R Sweeney,Jonathan Busquets,Atul Singh Rathore,Qing Deng,Michael R Green,Steven Grant,Susan Demo,Gaurav S Choudhary,Srabani Sahu,Beamon Agarwal,Mason Spodek,Victor Thiruthuvanathan,Britta Will,Ulrich Steidl,George D Tippett,Jan Burger,Gautam Borthakur,Elias Jabbour,Naveen Pemmaraju,Tapan Kadia,Steven Kornblau,Naval G Daver,Kiran Naqvi,Nicholas J Short,Guillermo Garcia-Manero,Stefano Tiziani,Amit Verma,Marina Konopleva
DOI: https://doi.org/10.1038/s43018-024-00811-3
Abstract:Malignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine (AZA), followed by a single-arm, open-label, phase 1b/2 study in persons with advanced myelodysplastic syndrome (MDS). The dual primary endpoints evaluated clinical activity, safety and tolerability; secondary endpoints evaluated pharmacokinetics, pharmacodynamics, overall survival, event-free survival and duration of response. The dose-escalation study included six participants and the dose-expansion study included 24 participants. Therapy was well tolerated and led to an objective response rate of 70% with (marrow) complete remission in 53% of participants and a median overall survival of 11.6 months, with evidence of myeloid differentiation in responders determined by single-cell RNA sequencing. Glutamine transporter solute carrier family 38 member 1 in MDS stem cells was associated with clinical responses and predictive of worse prognosis in a large MDS cohort. These data demonstrate the safety and efficacy of CB-839 and AZA as a combined metabolic and epigenetic approach in MDS. ClinicalTrials.gov identifier: NCT03047993 .